Is Aclaris Therapeutics, Inc. (NASDAQ:ACRS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aclaris Therapeutics, Inc. at current levels.
TSLP biology is the next billion-dollar respiratory and dermatology battleground, and Aclaris owns two shots at it for the price of a small-cap rounding error.
Where ACRS is headed
Aclaris in 2028 looks nothing like the company sitting at $4.32 today. The pipeline has two assets pointed at the same target that Amgen and AstraZeneca already validated by spending $14 billion on Tezspire-class biology. Bosakitug (ATI-045) is the anti-TSLP monoclonal that, if Phase 2 atopic dermatitis data lands cleanly in the back half of 2026, becomes a partnership conversation with every large-cap immunology shop that missed out on Horizon and Prometheus. ATI-052, the TSLP/IL-4R bispecific, is the more interesting bet, because every dermatologist and pulmonologist already knows what dupilumab does for IL-4R, and a single-injection bispecific that hits both pathways is the kind of asset Sanofi or Regeneron would write a very large check to neutralize before it reaches Phase 3.
Read the full Compass Direction on ACRS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $4.32).
See the full ACRS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Aclaris Therapeutics, Inc. (NASDAQ:ACRS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aclaris Therapeutics, Inc. at current levels. TSLP biology is the next billion-dollar respiratory and dermatology battleground, and Aclaris owns two shots at it for the price of a small-cap rounding error.
What is ACRS's Compass Score?
Aclaris Therapeutics, Inc. scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for ACRS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ACRS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.